Tilburg University

Relationship between myeloperoxidase promotor polymorphism and disease severity in sarcoidosis

Rothkrantz-Kos, S.; Drent, M.; Rutgers, A.; Heeringa, P.; de Vries, J.; Dieijen-Visser, M.P.; Cohen Tervaert, J.W.

Published in:
European Journal of Internal Medicine

Publication date:
2003

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Tilburg University Research Portal](#)

Citation for published version (APA):
Rothkrantz-Kos, S., Drent, M., Rutgers, A., Heeringa, P., de Vries, J., Dieijen-Visser, M. P., & Cohen Tervaert, J. W. (2003). Relationship between myeloperoxidase promotor polymorphism and disease severity in sarcoidosis. *European Journal of Internal Medicine*, 14(5), 296-301.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Original article

Relationship between myeloperoxidase promotor polymorphism and disease severity in sarcoidosis[☆]

Snježana Rothkrantz-Kos^{a,d,f}, Marjolein Drent^{b,d,f,*}, Abraham Rutgers^c, Peter Heeringa^c,
Jolanda De Vries^{c,f}, Marja P. van Dieijen-Visser^{a,f}, Jan W. Cohen Tervaert^{c,f}

^aDepartment of Clinical Chemistry, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands

^bDepartment of Respiratory Medicine, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands

^cDepartment of Immunology, University Hospital Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands

^dNutrition and Toxicology Research Institute Maastricht (NUTRIM), Maastricht, The Netherlands

^eDepartment of Clinical Health Psychology, Tilburg University, Tilburg, The Netherlands

^fSarcoidosis Management Center, Maastricht, The Netherlands

Received 5 November 2002; accepted 11 March 2003

Abstract

Background: Previously, we demonstrated that the number of polymorphonuclear neutrophils (PMNs) in bronchoalveolar lavage fluid (BALF) is useful in distinguishing sarcoidosis patients with a favorable outcome from those having a more severe course of disease. Neutrophils contain the oxidant-generating enzyme myeloperoxidase (MPO). Cellular levels of MPO can be influenced by functional promotor polymorphisms, –463G/A and –129G/A, which may modify disease severity. **Methods:** In the present study, we investigated two MPO promotor polymorphisms in 110 sarcoidosis patients and in 191 ethnically matched controls. Pulmonary disease severity was evaluated by means of radiographic staging, HRCT scoring, lung function, and exercise capacity testing. **Results:** No significant differences were found between sarcoidosis patients and healthy controls with regard to either polymorphism. Nor was any association observed between –463 G/A and –129 G/A polymorphism and the severity of sarcoidosis. **Conclusions:** The functional MPO promotor polymorphisms –463G/A and –129G/A did not explain disease severity in the sarcoidosis population studied. Future studies are needed to identify predictive features useful in guiding therapeutic strategies and to determine difficult-to-treat cases.

© 2003 Elsevier B.V. All rights reserved.

Keywords: Myeloperoxidase; Sarcoidosis; Neutrophils; Polymorphism; Granuloma

1. Introduction

Sarcoidosis, a disease predominantly affecting young adults, is the most common diffuse lung disease with a population prevalence of around 1:4000 [1,2]. Sarcoidosis is an immune-mediated inflammatory disease with un-

known etiology, although genetic predisposition is likely to be important [2,3]. The main pathologic feature of the disease is a chronic inflammation resulting in non-caseating granuloma formation. The prognosis of sarcoidosis is rather variable. A great deal of uncertainty exists as to how to predict the natural course of the (untreated) disease and how to identify those individual cases who should be treated immediately. More important, as it is still not possible to identify the cause of sarcoidosis, therapy is directed at controlling the inflammatory reaction [4].

Bronchoalveolar lavage fluid (BALF) analysis appears to reflect the severity of sarcoidosis [5–9]. Notably, the number of polymorphonuclear neutrophils (PMNs) is

[☆]Data from this manuscript were partly presented at the 7th World Association of Sarcoidosis and Other Granulomatous Disorders, 16–19 June, 2002, Stockholm, Sweden.

*Corresponding author. Tel.: +31-43-3877-043; fax: +31-43-3875-051.

E-mail address: mdr@slon.azm.nl (M. Drent).

increased in advanced, chronic sarcoidosis [5–7,9]. In line with these findings, interleukin 8 (IL-8)—a potent chemoattractant and activator of neutrophils—in BALF appears to be highly elevated in sarcoidosis patients who show progressive disease [8,10]. Myeloperoxidase (MPO) is an abundant protein in PMNs and monocytes, stored in the azurophilic granules of neutrophils and released during phagocytosis [11,12]. MPO in BALF originates from lung PMNs and can be used to estimate the presence and/or activation of PMNs [13]. Indeed, a strong correlation between MPO level and PMN count in BALF has been demonstrated in patients with Wegener's granulomatosis [14]. MPO concentrations appear to be associated with two described functional promotor polymorphisms, namely, the –463 G/A MPO promotor polymorphism [15,16] and the recently described –129 G/A promotor polymorphism [17]. Several diseases have been reported to be associated with the –463 G/A promotor polymorphism [16,18–22], whereas no association studies of –129 G/A have yet been reported.

MPO appears to be involved in tissue damage through production of the potent oxidant HOCl, which is able to oxidize many cellular compounds, such as thiols and NADPH, and to lead to chlorination of DNA bases and tyrosine residues in proteins [11,12,23–25]. Therefore, it can be assumed that decreased availability of MPO, related to functional MPO promotor polymorphisms, has a protective effect by decreasing the chance of tissue damage.

It has been hypothesized that the MPO polymorphism may contribute, at least in part, to disease severity in sarcoidosis and make it possible to determine those cases who might benefit from agents controlling the inflammatory reaction at an early stage. Hence, the incidence of two MPO promotor polymorphisms (–463 G/A and –129 G/A) was analyzed in a Dutch Caucasian sarcoidosis population, as was their possible relationship with disease severity.

2. Materials and methods

2.1. Study population

Caucasian sarcoidosis patients ($n=110$) who visited the Sarcoidosis Management Center of the University Hospital Maastricht, a Dutch referral center for sarcoidosis, between January 2000 and April 2001 were included in this study. Patients were diagnosed based on consistent clinical features and BALF analysis, according to the ATS/ERS/WASOG guidelines [2,26]. The diagnosis was histologically confirmed in 85% of the cases. The control population consisted of 191 healthy individuals. Informed consent was obtained from all participating subjects. Patient characteristics are summarized in Table 1.

Table 1

Characteristics of the Dutch Caucasian sarcoidosis patients and controls genotyped for –463 G/A and –129 G/A myeloperoxidase (MPO) promotor polymorphism

	Sarcoidosis patients	Control subjects
	($n=110$)	($n=191$)
Male/female (n)	55/55	100/91
Age ^a (years)	40.7±11.0 (17–70)	36.4±14.4 (18–82)
Time since diagnosis ^a (years)	4.25±5.67 (0–37)	–
Smoking (no/yes) (n)	101/9	–
Prednisone (no/yes) (n)	78/32	–

^a Data are expressed as mean±S.D. with range in parentheses.

2.2. Evaluating sarcoidosis pulmonary disease severity

Chest radiographs were graded according to the radiographic staging of DeRemee (0 to III), adding stage IV, the end stage of lung fibrosis [2,27]. With high-resolution computer tomography (HRCT), thin-section scans with 1-mm collimation were obtained at 10-mm intervals through the chest. The scanning parameters included 137 kVp, 255 mA, and 1-s scanning time.

Both mediastinal (width 400 HU; level 40 HU) and lung (width 1600 HU; level –800 HU) window images were obtained. The semiquantitative HRCT scoring system was used as described previously [28].

Lung function parameters, including the forced expiratory volume in 1 s (FEV₁) and forced vital capacity (FVC), were measured with a pneumotachograph. The diffusing capacity for carbon monoxide (DL_{CO}) was measured using the single-breath method (both Masterlab, Jaeger, Würzburg, Germany). Values were expressed as a percentage of those predicted [29].

Serum ACE (sACE) was measured using the colorimetric method (Fujirebio Inc., Tokyo, Japan, cat. nr. FU 116). ACE acts on a substrate *p*-hydroxybenzoyl-glycyl-L-hydroxy-L-leucine and separates *p*-hydroxybenzoyl-glycine, which is converted in two consequent reactions in quinoneimine dye. The absorbance of quinoneimine dye is measured at 505 nm to evaluate the ACE activity.

Soluble interleukin-2 receptor (sIL2R) was measured on the IMMULITEAutomated Analyser, which is a two-site chemiluminescent enzyme immunometric assay with a detection limit of 50 kU/l and a measuring range of 50–7500 kU/l (Diagnostic Product Corporation, Los Angeles, CA, cat no LKIP1).

2.3. Molecular studies

The –463 G/A polymorphism was determined as previously described [16,18,19]. The 129G/A polymorphism was determined as described by Hoy et al. [17]. The

Table 2

Sequences of primers and digestion fragment lengths used for myeloperoxidase (MPO) genotyping

MPO Promotor	Primers	Digestion of PCR product	Genotype (characterized by fragments in bp)
–463 G/A	5'-CGGTATAGGCACACAATGGTGAG 5'-R-GCAATGGTTCAAGCGATTCTTC	Aci I	GG (168, 121, 61) GA (289, 168, 121, 61) AA (289, 61)
–129 G/A	5'-CCTCCACAGCTCACCTGATAT 5'-R-CGCTTGAACCATTCACATCA	Apa I	GG (124) GA (154)

most important features are presented in Table 2. When screening for 129 G/A polymorphism, we identified a 129G to A specific ApaI restriction site within the 278 bp PCR product. PCR products were digested with 20 units of ApaI (Roche, Mijdrecht, the Netherlands) for 2 h or overnight at 30 °C, separated on a 2% agarose gel, and stained with ethidium-bromide.

2.4. Statistics

All analyses were performed using SPSS 10.0 for Windows (SPSS, Chicago, IL, USA). Agreement with Hardy–Weinberg equilibrium and differences in allele and genotype frequencies between groups were tested using chi-square tests. Because multiple comparisons were performed, a probability value divided by the number of comparisons was considered statistically significant (Bonferroni's correction). Univariate logistic regression analysis was used to calculate odds ratios with 95% confidence intervals. Group comparisons were performed by means of an Independent samples *t*-test or the Mann–Whitney *U*-test.

3. Results

The two functional MPO polymorphisms fulfilled Hardy–Weinberg expectations in both sarcoidosis and control subjects. Genotype distributions associated with the –463 G/A or –129 G/A polymorphism did not differ significantly between patients with sarcoidosis and healthy controls (Table 3). Furthermore, for both polymorphisms, sex-specific analysis showed no differences in allele or genotype frequencies (data not shown).

Baseline clinical data of the patients with sarcoidosis are presented in Table 4. We also tested whether any association could be found with MPO polymorphisms. For this purpose, for –463 G/A polymorphism, the GA and AA genotypes were grouped together and compared to the GG genotype. No relationship with age at diagnosis was found. Severity of the disease was then evaluated in relation to genotype. The results of this analysis are presented in Table 5. As can be seen, no significant differences in the severity, as presented by clinical data, could be found. This finding remained unchanged after correcting for prednisone use. The same analysis that is shown in Table 5 was

Table 3

Genotype frequencies of the myeloperoxidase (MPO) promotor polymorphisms in the Dutch Caucasian sarcoidosis and control populations^a

Classification		Sarcoidosis patients (<i>n</i> = 110)	Control subjects (<i>n</i> = 191)	OR (95% C.I.)	<i>P</i> -value ^b
Polymorphism					
–463 G/A					
Genotype	GG	67 (60.9%)	113 (59.2%)	1.0	0.942
	GA ^c	37 (33.6%)	68 (35.6%)	1.01 (0.35–2.91)	
	AA ^c	6 (5.5%)	10 (5.2%)	0.91 (0.56–1.52)	
Allele	G	171 (77.7%)	294 (77.0%)	1.0	0.829
	A ^c	49 (22.3%)	88 (23%)	0.95 (0.64–1.42)	
–129 G/A ^d					
Genotype	GG ^c	97 (88.2%)	167 (87.4%)	1.0	0.849
	GA ^c	13 (11.8%)	24 (12.6%)	0.93 (0.45–1.91)	
Allele	G	207 (94.1%)	358 (93.7%)	1.0	0.854
	A ^c	13 (5.9%)	24 (6.3%)	0.93 (0.46–1.88)	

^a Data are expressed as absolute numbers with percentages in parentheses.

^b P values are for overall comparison between cases and control subjects (chi-square analysis). Odds ratios (OR) for genotypes/alleles were calculated by logistic regression analysis.

^c GG genotype or G allele is the reference group.

^d AA genotype was absent from both the sarcoidosis and control groups.

Table 4

Evaluation of severity in a Dutch Caucasian sarcoidosis patient population^a

	Sarcoidosis population		
	Female (n=55)	Male (n=55)	Total (n=110)
sACE (9–25 U/l)	20.0 (17–26)	20.0 (15–28)	20.0 (16–27)
sIL2R (241–846 kU/l)	550 (404–937)	767 (409–1180)	667 (408–1085)
FEV ₁ (% pred) ^b	97.0 (84–106)	87.0 (63–99)	92.0 (69.8–103)
FVC (% pred) ^b	105 (94.2–115)	91.0 (77.5–102)	98.5 (84.5–110)
DL _{CO} (% pred)	89 (78–96)	85.5 (72.5–97.5)	87.0 (76.5–96.5)
CXR	17/8/14/14/2	4/8/14/20/9	21/16/28/34/11
0/I/II/III/IV ^b			
HRCT _{tot} (0–18) ^b	4.0 (1–6)	6.0 (3–9)	5.0 (3–8)

Abbreviations: sACE, serum Angiotensin-converting enzyme; sIL2R, soluble IL2 receptor; FEV₁, forced expiratory volume in 1s; FVC, forced vital capacity; DL_{CO}, diffusing capacity for carbon monoxide; CXR, Chest radiographic stage, HRCT_{tot}, high-resolution computer tomography total score.

^a Data are median with interquartile range (25th–75th percentile) in parentheses, except for radiographic staging.

^b $P < 0.01$ comparing males and females.

repeated with respect to –129 G/A polymorphism. No relationship to clinical data was found (data not shown).

4. Discussion

This study showed that the distribution of two functional MPO promotor polymorphisms, –463G/A and –129G/A, was similar in both sarcoidosis patients and controls. No relationship was found between these polymorphisms and disease severity. To exclude a possible bias due to

corticosteroid use, treated and untreated sarcoidosis patients were also considered separately. The results in both subgroups appeared to be similar to those in the total population, i.e. no relationship to MPO genotype (also after stratification for sex and age) was found.

Of the cells present in BALF, PMNs are considered to be a key mediator indicative of severity of the disease. In cases with more extensive long-term radiographic features, impaired lung function parameters, a poor prognosis, and sometimes corticosteroid-resistant chronic disease, PMNs were found to be increased in BALF [5–7,9]. Moreover, a

Table 5

Relationship between the –463 G/A myeloperoxidase (MPO) promotor polymorphism and disease severity in a Dutch Caucasian sarcoidosis population (n=110)^a

Diagnostic parameter	Female		Male	
	GG (n=32)	GA/AA (n=23)	GG (n=35)	GA/AA (n=20)
sACE (9–25 U/l)	20 (18–26)	20 (16–27)	23 (15–27)	18.5 (15.3–32.8)
sIL2R (241–846 kU/l)	511 (397–806)	732 (414–1581)	801 (409–1180)	664 (409–1181)
FEV ₁ (% pred)	99 (88–107)	92 (71–106)	79 (61–100)	90 (73–96)
FVC ⁺ (% pred)	105 (96–115)	105 (88–114)	89 (75–105)	95 (86–100)
DL _{CO} (% pred)	89 (81–95)	87 (72–99)	83 (69–96)	92 (80–102)
CXR	11/8/6/7/0	6/0/8/7/2	3/5/7/13/7	1/3/7/7/2
0/I/II/III/IV				
HRCT _{tot} (0–18)	3 (1–5)	6 (2–7)	7 (4–9)	6 (3–9)

sACE, serum Angiotensin-converting enzyme; CXR, Chest radiographic stage; FEV₁, forced expiratory volume in 1s; FVC, forced vital capacity; DL_{CO}, diffusing capacity for carbon monoxide; sIL2R, soluble IL2 receptor; HRCT_{tot}, high-resolution computer tomography total score.

^a Data are median with interquartile range (25th–75th percentile) in parentheses, except for radiographic staging.

strong correlation exists between MPO level and PMN count in BALF [14].

Some could argue that the neutrophils might just be an epiphenomenon, appearing when disease is extensive and fibrotic. However, it was recently demonstrated that the number of neutrophils in BALF, even at first presentation, is indicative of prognosis and disease outcome [5,9].

The GG genotype of -463 G/A polymorphism was previously found to correlate with higher levels of MPO mRNA and higher protein levels, as shown by Western blotting, than the GA or AA genotype [15]. In contrast, when circulating levels of MPO were measured in serum by means of enzyme immunoassay, no such correlation was found with -463 G/A polymorphism, but only with -129 G/A polymorphism [17].

It was recently demonstrated that -463 G/A MPO promotor polymorphism influences diseases severity and expression in chronic granulomatous disease [22] and Wegener's granulomatosis [20], both granulomatous diseases different from sarcoidosis. In the present study, however, no association of MPO promotor polymorphisms with sarcoidosis were found. One possible explanation could be that disease expression in chronic granulomatous disease and Wegener's granulomatosis is characterized by infections with extensive PMN involvement. Indeed, cotrimoxazole, an antibacterial drug, positively influences the course of disease in both chronic granulomatous disease [30] and Wegener's granulomatosis [31,32], whereas this has never been shown in sarcoidosis.

Granuloma formation in sarcoidosis appears to be a strictly T-cell-dependent process [33]. Since MPO was shown to inhibit T-cell proliferation [34,35], one can postulate that MPO promotor polymorphisms might also influence the T-cell-dependent disease process in sarcoidosis. Therefore, the role of MPO and its polymorphisms seem very complex and not completely defined in the different diseases that are characterized by granulomatous inflammation.

In conclusion, the PMN count in BALF appears to be useful in determining chronic and difficult-to-treat sarcoidosis patients. MPO plays a key role in the immunopathogenesis of several granulomatous disorders and MPO release appears to be related to MPO polymorphism(s). However, in the Dutch Caucasian sarcoidosis population studied, similar frequencies of functional MPO promotor polymorphisms (-463 G/A and -129 G/A) were found as compared to control subjects. Furthermore, no association between -463 G/A and -129 G/A MPO promotor polymorphisms and the severity of sarcoidosis, including radiographic features, impaired lung function, time since diagnosis and corticosteroid use, was found in our study population. As we are unable to identify the cause of sarcoidosis, therapy must be focused on controlling the inflammatory reaction. Future studies are needed to determine those cases with a more advanced chronic course

of the disease who might benefit from early treatment of the inflammatory reaction.

Acknowledgements

The authors gratefully acknowledge Ruud Teunissen and Petal Wijnen for their assistance and Professor Dr J. Geraedts, clinical geneticist, for his suggestions.

References

- [1] Foley PJ, Mullighan CG, McGrath DS, Pantelidis P, Marshall S, Lympay PA, Welsh KI, du Bois RM. Mannose-binding lectin promoter and structural gene variants in sarcoidosis. *Eur J Clin Invest* 2000;30:549–52.
- [2] Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, Rose C, Selroos O, Semenzato G, Sharma OP. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. *Sarcoidosis Vasc Diffuse Lung Dis* 1999;16:149–73.
- [3] Newman LS, Rose CS, Maier LA. Sarcoidosis. *N Engl J Med* 1997;336:1224–34.
- [4] Baughman RP. Can persistent tumor necrosis factor release lead to refractory sarcoidosis? *Sarcoidosis Vasc Diffuse Lung Dis* 2002;19:164–6.
- [5] Drent M, Jacobs JA, de Vries J, Lamers RJ, Liem IH, Wouters EF. Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? *Eur Respir J* 1999;13:1338–44.
- [6] Roth C, Huchon GJ, Arnoux A, Stanislas-Leguern G, Marsac JH, Chretien J. Bronchoalveolar cells in advanced pulmonary sarcoidosis. *Am Rev Respir Dis* 1981;124:9–12.
- [7] Lin YH, Haslam PL, Turner-Warwick M. Chronic pulmonary sarcoidosis: relationship between lung lavage cell counts, chest radiograph, and results of standard lung function tests. *Thorax* 1985;40:501–7.
- [8] Car BD, Meloni F, Luisetti M, Semenzato G, Gialdroni-Grassi G, Walz A. Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. *Am J Respir Crit Care Med* 1994;149:655–9.
- [9] Ziegenhagen M, Rorhe M, Schlaak M, Muller-Quernheim J. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. *Eur Respir J* 2003;21:407–13.
- [10] Takizawa H, Satoh M, Okazaki H, Matsuzaki G, Suzuki N, Ishii A, Suko M, Okudaira H, Morita Y, Ito K. Increased IL-6 and IL-8 in bronchoalveolar lavage fluids (BALF) from patients with sarcoidosis: correlation with the clinical parameters. *Clin Exp Immunol* 1997;107:175–81.
- [11] Winterbourn CC, Vissers MC, Kettle AJ. Myeloperoxidase. *Curr Opin Hematol* 2000;7:53–8.
- [12] Klebanoff SJ. Myeloperoxidase. *Proc Assoc Am Physicians* 1999;111:383–9.
- [13] Schmekel B, Karlsson SE, Linden M, Sundstrom C, Tegner H, Venge P. Myeloperoxidase in human lung lavage. I. A marker of local neutrophil activity. *Inflammation* 1990;14:447–54.
- [14] Schnabel A, Csernok E, Braun J, Gross WL. Activation of neutrophils, eosinophils, and lymphocytes in the lower respiratory tract in Wegener's granulomatosis. *Am J Respir Crit Care Med* 2000;161:399–405.
- [15] Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M,

- Reynolds WF. An Alu element in the myeloperoxidase promoter contains a composite SP1 thyroid hormone–retinoic acid response element. *J Biol Chem* 1996;271:14412–20.
- [16] Reynolds WF, Chang E, Douer D, Ball ED, Kanda V. An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. *Blood* 1997;90:2730–7.
- [17] Hoy A, Tregouet D, Leininger-Muller B, Poirier O, Maurice M, Sass C, Siest G, Tired L, Visvikis S. Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms. *Eur J Hum Genet* 2001;9:780–6.
- [18] Cascorbi I, Henning S, Brockmoller J, Gephart J, Meisel C, Muller JM, Loddenkemper R, Roots I. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant –463A of the myeloperoxidase gene. *Cancer Res* 2000;60:644–9.
- [19] London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. *Cancer Res* 1997;57:5001–3.
- [20] Reynolds WF, Stegeman CA, Cohen Tervaert JW. –463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA associated vasculitis. *Clin Immunol* 2002;103:154–60.
- [21] Reynolds WF, Hiltunen M, Pirskanen M, Mannermaa A, Helisalmi S, Lehtovirta M, Alafuzoff I, Soininen H. MPO and APOEepsilon4 polymorphisms interact to increase risk for AD in Finnish males. *Neurology* 2000;55:1284–90.
- [22] Foster CB, Lehnbecher T, Mol F, Steinberg SM, Venzon DJ, Walsh TJ, Noack D, Rae J, Winkelstein JA, Curnutte JT, Chanock SJ. Host defense molecule polymorphisms influence the risk for immune mediated complications in chronic granulomatous disease. *J Clin Invest* 1998;102:2146–55.
- [23] Winterbourn CC, Kettle AJ. Biomarkers of myeloperoxidase-derived hypochlorous acid. *Free Radic Biol Med* 2000;29:403–9.
- [24] Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, van der Vliet A. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. *Nature* 1998;391:393–7.
- [25] Burner U, Furtmuller PG, Kettle AJ, Koppenol WH, Obinger C. Mechanism of reaction of myeloperoxidase with nitrite. *J Biol Chem* 2000;275:20597–601.
- [26] Drent M, Jacobs JA, Cobben NAM, Costabel U, Wouter EFM, Mulder PGH. Computer program supporting the diagnostic accuracy of cellular BALF analysis: a new release. *Respir Med* 2001;95:781–6.
- [27] DeRemee RA. The roentgenographic staging of sarcoidosis. Historic and contemporary perspectives. *Chest* 1983;83:128–33.
- [28] Oberstein A, von Zitzewitz H, Schweden F, Muller-Quernheim J. Non invasive evaluation of the inflammatory activity in sarcoidosis with high-resolution computed tomography. *Sarcoidosis Vasc Diffuse Lung Dis* 1997;14:65–72.
- [29] Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests. European Community for Steel and Coal. Official Statement of the European Respiratory Society. *Eur Respir J Suppl* 1993;16:5–40.
- [30] Cale CM, Jones AM, Goldblatt D. Follow up of patients with chronic granulomatous disease diagnosed since 1990. *Clin Exp Immunol* 2000;120:351–5.
- [31] Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. *N Engl J Med* 1996;335:16–20.
- [32] DeRemee RA. The treatment of Wegener's granulomatosis with trimethoprim/sulfamethoxazole: illusion or vision? *Arthritis Rheum* 1988;31:1068–74.
- [33] Agostini C, Basso U, Semenzato G. Cells and molecules involved in the development of sarcoid granuloma. *J Clin Immunol* 1998;18:184–92.
- [34] el-Hag A, Clark RA. Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. *J Immunol* 1987;139:2406–13.
- [35] van der Veen RC, Dietlin TA, Hofman FM, Pen L, Segal BH, Holland SM. Superoxide prevents nitric oxide-mediated suppression of helper T lymphocytes: decreased autoimmune encephalomyelitis in nicotinamide adenine dinucleotide phosphate oxidase knockout mice. *J Immunol* 2000;164:5177–83.